Adjuvant Chemotherapy in Bladder Cancer

Neo-adjuvant and adjuvant chemotherapy in bladder cancer.

Transitional cell carcinoma of the bladder represents the second most common genitourinary malignancy [1]; the clinical approach to muscle-invasive disease has been modified in the last decade, considering the important role of multidisciplinary team, including surgeon, oncologist and radiotherapist. In fact, despite relevant progress in surgical management of these patients, the global prognos...

Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy

OBJECTIVES To compare the outcomes of adjuvant chemotherapy (AC) versus observation in patients with non-organ confined disease after neoadjuvant chemotherapy and radical cystectomy (RC). MATERIALS AND METHODS Using the National Cancer Database, we identified patients who received NAC prior to RC and had advanced stage (pT3/4) or pathologically involved nodes (pN+) at the time of surgery from...

Perioperative chemotherapy: the case for adjuvant chemotherapy for muscle-invasive bladder cancer.

Neoadjuvant chemotherapy in bladder cancer

The use of neoadjuvant chemotherapy is an important element in the management of advanced bladder cancer. While definitive surgical management of locally advanced disease remains the gold standard of treatment, evidence over the years has repeatedly and consistently demonstrated the survival benefits of presurgical systemic chemotherapy. Incorporation of neoadjuvant chemotherapy into the treatm...

Adjuvant Chemotherapy of Colorectal Cancer.

Advances have been made in the adjuvant therapy of colorectal cancers. Fluorouracil-based chemotherapy has now been demonstrated to improve long-term disease-free survival rates in patients with resected stage III colon cancer. Combined radiation therapy plus fluorouracil-based chemotherapy has been shown to improve both local control and disease-free survival in patients with stage II and III ...